CN106536753B - 用于确定对mek/erk抑制剂的应答性的方法 - Google Patents

用于确定对mek/erk抑制剂的应答性的方法 Download PDF

Info

Publication number
CN106536753B
CN106536753B CN201580028218.0A CN201580028218A CN106536753B CN 106536753 B CN106536753 B CN 106536753B CN 201580028218 A CN201580028218 A CN 201580028218A CN 106536753 B CN106536753 B CN 106536753B
Authority
CN
China
Prior art keywords
gly
leu
ser
pro
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580028218.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106536753A (zh
Inventor
郭晟
钱武斌
宁金鹰
张晶
李际仙
梅竹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Bioscience Inc Taicang
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Priority to CN202010591503.6A priority Critical patent/CN111808957A/zh
Publication of CN106536753A publication Critical patent/CN106536753A/zh
Application granted granted Critical
Publication of CN106536753B publication Critical patent/CN106536753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580028218.0A 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法 Active CN106536753B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010591503.6A CN111808957A (zh) 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410135569 2014-04-04
CN2014101355699 2014-04-04
PCT/CN2015/075884 WO2015149721A1 (en) 2014-04-04 2015-04-03 Methods for determining responsiveness to mek/erk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010591503.6A Division CN111808957A (zh) 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法

Publications (2)

Publication Number Publication Date
CN106536753A CN106536753A (zh) 2017-03-22
CN106536753B true CN106536753B (zh) 2020-07-21

Family

ID=54239415

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580028218.0A Active CN106536753B (zh) 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法
CN201580029656.9A Active CN106460060B (zh) 2014-04-04 2015-04-03 Hnf4g-rspo2融合基因及其在癌症治疗中的用途
CN202010591503.6A Pending CN111808957A (zh) 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201580029656.9A Active CN106460060B (zh) 2014-04-04 2015-04-03 Hnf4g-rspo2融合基因及其在癌症治疗中的用途
CN202010591503.6A Pending CN111808957A (zh) 2014-04-04 2015-04-03 用于确定对mek/erk抑制剂的应答性的方法

Country Status (7)

Country Link
US (3) US10683550B2 (de)
EP (3) EP3126521B1 (de)
CN (3) CN106536753B (de)
DK (2) DK3126521T3 (de)
ES (2) ES2727374T3 (de)
PT (2) PT3126521T (de)
WO (2) WO2015149720A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563550A (zh) * 2016-08-04 2019-04-02 静冈县 判定有无癌症发病风险的方法
CN110139875B (zh) * 2016-09-30 2023-03-03 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
CN113498341A (zh) * 2019-01-02 2021-10-12 浙江冠科美博生物科技有限公司 使用多靶点激酶抑制剂结合蛋白激酶生物标志物的癌症治疗
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0390323A2 (de) * 1989-03-29 1990-10-03 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
CN103402517A (zh) * 2010-11-19 2013-11-20 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
JP2001507563A (ja) 1995-11-23 2001-06-12 キャンサー リサーチ キャンペーン テクノロジー リミテッド Ｂｒｃａ２癌感受性遺伝子の同定及び配列決定に関する材料及び方法並びにそれらの使用
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900021A1 (ru) 1996-07-13 1999-08-26 Глаксо, Груп Лимитед Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
HUP0100287A3 (en) 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
PT2050749T (pt) 2006-08-08 2018-01-02 Chugai Pharmaceutical Co Ltd Derivado de pirimidina como inibidador de pi3k e sua utilização
KR20090071603A (ko) 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
CN101524529B (zh) 2008-03-04 2011-09-28 中国人民解放军第二军医大学 HNF4α诱导分化治疗人体恶性实体瘤
CN102439174B (zh) 2009-02-19 2015-02-04 康奈尔大学 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
EP2424567B1 (de) * 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Verfahren zur herstellung von heteromultimeren molekülen
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012106559A1 (en) 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
CN103571848B (zh) 2012-08-10 2016-06-29 安徽医科大学第一附属医院 点状掌跖角化病的致病基因及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0390323A2 (de) * 1989-03-29 1990-10-03 The Johns Hopkins University Nachweis des Ausfalls des Wildtyps des p53-Gens
CN103402517A (zh) * 2010-11-19 2013-11-20 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial;Gerald S Falchook 等;《Lancet Oncol》;20120831;第13卷(第8期);第782-789页 *
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors;Erick J. Morris 等;《CANCER DISCOVERY》;20130731;第3卷(第7期);第742-750页 *
p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells;Rieber M 等;《Biochem Pharmacol》;20140315;第88卷(第2期);第169-177页 *
Rieber M 等.p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells.《Biochem Pharmacol》.2014,第88卷(第2期),第169-177页. *

Also Published As

Publication number Publication date
EP4012049A3 (de) 2022-08-24
CN106460060B (zh) 2020-02-11
EP4012049A2 (de) 2022-06-15
ES2896404T3 (es) 2022-02-24
CN106460060A (zh) 2017-02-22
WO2015149720A1 (en) 2015-10-08
PT3126521T (pt) 2019-06-27
EP3126528A1 (de) 2017-02-08
EP3126521B1 (de) 2019-03-20
EP3126528B1 (de) 2021-08-18
DK3126528T3 (da) 2021-11-08
WO2015149721A1 (en) 2015-10-08
US20180282814A1 (en) 2018-10-04
US20200123622A1 (en) 2020-04-23
CN111808957A (zh) 2020-10-23
EP3126521A1 (de) 2017-02-08
EP3126521A4 (de) 2017-11-08
CN106536753A (zh) 2017-03-22
ES2727374T3 (es) 2019-10-15
PT3126528T (pt) 2021-09-09
US20170114414A1 (en) 2017-04-27
US10683550B2 (en) 2020-06-16
DK3126521T3 (da) 2019-06-17
EP3126528A4 (de) 2018-02-21
US10501805B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
US5955306A (en) Genes encoding proteins that interact with the tub protein
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
CA2394229C (en) Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
KR20150027752A (ko) 인간화된 il-7 설치류
CN101641451A (zh) chr8q24.21上的癌症易感性变体
JP2015109806A (ja) 新規ｒｅｔ融合体の検出法
CN101258249A (zh) 检测黑素瘤的方法和试剂
CN106536753B (zh) 用于确定对mek/erk抑制剂的应答性的方法
GB2424886A (en) Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
JPWO2012014795A1 (ja) 新規ｒｅｔ融合体の検出法
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
US20050170500A1 (en) Methods for identifying risk of melanoma and treatments thereof
CN113544257A (zh) 中国仓鼠卵巢细胞中内源性逆转录病毒的表征及灭活
US20050277118A1 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
US20080199480A1 (en) Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
KR102661616B1 (ko) Gpr156 변이체 및 이들의 용도
CA2482907A1 (en) Tissue specific genes and gene clusters
US11459613B2 (en) Methods of characterizing resistance to modulators of Cereblon
JP2003527091A (ja) 新規カルパインプロテアーゼ２６１７６およびその使用
WO2006022633A1 (en) Methods for identifying a risk of type ii diabetes and treatments thereof
JP2003235575A (ja) 哺乳動物において機能的なトランスポゾン
TW202313972A (zh) 新ｎｒｇ１融合物、融合接合處及檢測彼等之方法
KR20230101839A (ko) 세이프 하버 유전자좌위
US20030165902A1 (en) Haplotypes of the F2R gene

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant